In recent years, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporters 2 inhibitors (SGLT-2Is) have been proved to reduce glucose level and risk of cardiovascular events in patients with hyperglycemia [47]. Here, GLP1R is linked to Hyperglycemia.